Valuation: Dermapharm Holding SE

Market Cap 1.91B 2.12B 1.78B 1.62B 3.03B 202B 3.05B 21.39B 8.35B 105B 7.97B 7.8B 337B P/E 2026 *
14.7x
P/E 2027 * 13x
Enterprise Value 2.72B 3.03B 2.54B 2.3B 4.32B 288B 4.35B 30.48B 11.9B 150B 11.36B 11.12B 481B EV / Sales 2026 *
2.25x
EV / Sales 2027 * 2.07x
Free-Float
10.7%
Yield 2026 *
2.65%
Yield 2027 * 2.96%
1 day+1.85%
1 week-0.90%
Current month-1.66%
1 month+1.72%
3 months-10.97%
6 months-15.18%
Current year-2.03%
1 week 37.85
Extreme 37.85
38.9
1 month 37.35
Extreme 37.35
39.95
Current year 34.3
Extreme 34.3
51.9
1 year 32.4
Extreme 32.4
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 01/08/2017
Director of Finance/CFO - 01/11/2022
Investor Relations Contact - 01/12/2018
Director TitleAgeSince
Chairman 70 01/08/2017
Director/Board Member 66 01/08/2017
Director/Board Member 78 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Buy

Chairman

380,000 0.7670%
07/01/26 Buy 150 0.0003%
07/01/26 Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
+1.85%-0.90%+17.89%-1.66% 2.1B
+3.62%+1.68%+48.80%+98.41% 1,040B
+2.13%-1.76%+33.04%+61.88% 599B
+3.32%+4.47%+23.72%+91.59% 485B
+3.80%+3.21%+73.99%+41.69% 350B
+3.09%+3.03%+29.59%+45.42% 345B
+2.82%+2.20%+17.90%+40.15% 272B
+3.40%+0.99%-3.44%+12.08% 244B
+3.21%+3.15%+45.01%+49.99% 223B
+3.80%+4.56%+29.59%+97.73% 183B
Average +2.90%+1.62%+31.61%+53.73% 374.49B
Weighted average by Cap. +2.66%+1.53%+36.77%+68.65%

Financials

2026 *2027 *
Net sales 1.21B 1.34B 1.13B 1.02B 1.92B 128B 1.93B 13.54B 5.29B 66.39B 5.05B 4.94B 214B 1.25B 1.4B 1.17B 1.06B 1.99B 133B 2B 14.05B 5.49B 68.91B 5.24B 5.12B 222B
Net income 137M 153M 128M 116M 218M 14.53B 219M 1.54B 600M 7.54B 573M 561M 24.25B 155M 173M 145M 131M 247M 16.44B 248M 1.74B 679M 8.53B 649M 635M 27.44B
Net Debt 812M 903M 758M 687M 1.29B 85.92B 1.3B 9.09B 3.55B 44.59B 3.39B 3.32B 143B 687M 764M 641M 581M 1.09B 72.7B 1.1B 7.69B 3B 37.73B 2.87B 2.81B 121B
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
14/10/26 €38.55 +1.85% 15,973
13/10/26 €37.85 -1.17% 10,213
12/10/26 €38.30 -0.26% 12,585
09/10/26 €38.40 +0.66% 11,821
08/10/26 €38.15 -1.93% 18,235
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.55EUR
Average target price
51.00EUR
Spread / Average Target
+32.30%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE